A1-R101||A2-R101||RA-ILD DELPHI CONSENSUS SCREENING ALGORITHM | Boehringer Ingelheim Pro

x

Registration Form

MMC / MCR No. (optional for CME points, Malaysia/Singapore HCPs only)

Institution

When do you usually screen for PPF (eg, PFTs, HRCT)?

When I recognize signs of an ILD from the clinical assessment

When the patient reports symptoms of an ILD

When I recognize that the patient is at high risk of developing ILD through assessment of risk factors (eg, demographics, disease manifestations, and antibody profiles)

I do not screen for ILD/PPF

When do you initiate antifibrotic treatment in PPF patients?

Immediately upon detection of first signs of progression regardless of the underlying disease and existing treatment

When pulmonary symptoms worsen

When immunosuppressants/disease-modifying antirheumatic drugs (DMARDs)/corticosteroids fail

I do not consider nor initiate antifibrotic treatment

I refer patients to a pulmonologist when I believe antifibrotic treatment is necessary

Information you provide when registering will be shared with the account owner and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

This webinar is for Health Care Professionals only. Upon submitting this registration, I am confirming that I am a Health Care Professional.

Nintedanib

Nintedanib_1

RA-ILD DELPHI CONSENSUS SCREENING ALGORITHM

01/08/2023 | Author: Boehringer Ingelheim

Document ID: PC-SG-102040

RELATED CONTENT